Aynı Virüs Farklı Seyir; Monosit Kemoatraktan Protein-1 ve Sürfaktan Protein-A Düzeyinin COVID-19 Hastalarında Klinik Seyir ve Prognozla İlişkisi
- 30 September 2021
- journal article
- research article
- Published by Bilimsel Tip Publishing House in Flora the Journal of Infectious Diseases and Clinical Microbiology
- Vol. 26 (3), 410-418
- https://doi.org/10.5578/flora.20219709
Abstract
Introduction: To date, over 165 million people have been infected in the COVID-19 pandemic caused by the novel coronavirus SARSCoV-2 which emerged in Wuhan, China in December 2019. This study examined the relation between serum monocyte chemoattractant protein-1 and surfactant protein-A levels and the clinical course and prognosis of COVID-19. Materials and Methods: The study included a total of 108 subjects. Those in the patient group (n = 88) were diagnosed with COVID19 using real-time PCR analysis of nasopharyngeal swab samples and treated in the Pulmonary Diseases Intensive Care Unit and the Infectious Diseases Department between March 24 and May 20. The control group (n= 20) included asymptomatic healthcare workers whose real-time PCR results during routine COVID-19 screening in our hospital were negative. Results: The COVID-19 patient group had significantly higher monocyte chemoattractant protein-1 and SP-A levels compared to the control group (p = 0.001, p = 0.001). Patients who developed macrophage activation syndrome had significantly higher monocyte chemoattractant protein-1 and surfactant protein-A levels than those who did not both at admission (p = 0.001, p = 0.001) and on day 5 of treatment (p = 0.05, p = 0.04). Similarly, monocyte chemoattractant protein-1 and surfactant protein-A levels were significantly higher in patients who developed acute respiratory distress syndrome compared to those who did not at both time points (p = 0.001 for all). Both parameters were significantly higher in non-surviving COVID-19 patients compared to survivors (p= 0.001 for both). Conclusion: Monocyte chemoattractant protein-1 and surfactant protein-A are on opposing sides of the inflammatory balance, and SP-A may be a pneumoprotein of importance in the presentation, course, prognosis, and possibly the treatment of COVID-19 in the future.Keywords
This publication has 14 references indexed in Scilit:
- Presumed Asymptomatic Carrier Transmission of COVID-19JAMA, 2020
- Can we use interleukin-6 (IL-6) blockade for coronavirus disease 2019 (COVID-19)-induced cytokine release syndrome (CRS)?Journal of Autoimmunity, 2020
- The Role of Cytokines including Interleukin-6 in COVID-19 induced Pneumonia and Macrophage Activation Syndrome-Like DiseaseAutoimmunity Reviews, 2020
- Remdesivir for severe acute respiratory syndrome coronavirus 2 causing COVID-19: An evaluation of the evidenceTravel Medicine and Infectious Disease, 2020
- Associations between immune-suppressive and stimulating drugs and novel COVID-19—a systematic review of current evidenceecancermedicalscience, 2020
- COVID-19: consider cytokine storm syndromes and immunosuppressionThe Lancet, 2020
- SARS-CoV-2 and COVID-19: The most important research questionsCell & Bioscience, 2020
- The epidemiology and pathogenesis of coronavirus disease (COVID-19) outbreakJournal of Autoimmunity, 2020
- Transcriptomic characteristics of bronchoalveolar lavage fluid and peripheral blood mononuclear cells in COVID-19 patientsEmerging Microbes & Infections, 2020
- Pathogenic human coronavirus infections: causes and consequences of cytokine storm and immunopathologySeminars in Immunopathology, 2017